Table 2.

Transplant outcomes in AML patients receiving FM vs FB RIC for allogeneic HCT

	FM vs FB (entire cohort), HR (95% CI)	FM vs FB (CR only cohort), HR (95% CI)
OS
≤3 mo	1.82 (1.36-2.45), P < .001*	2.70 (1.80-4.07), P < .001*
>3 mo	0.87 (0.76-1.00), P = .05	0.81 (0.68-0.95), P = .01*
LFS	0.89 (0.78-1.00), P = .05	0.87 (0.75-1.01), P = .06
NRM
≤3 mo	3.85 (2.46-6.03), P < .001*	5.09 (2.83-9.14), P < .001*
>3 mo	1.14 (0.88-1.47), P = .32	1.17 (0.88-1.57), P = .28
Relapse	0.65 (0.55-0.76), P < .001*	0.60 (0.49-0.73), P < .001*
GRFS	1.03 (0.91-1.15), P = .66	1.01 (0.87-1.16), P = .92

^*Significant P value.